If you didn't find what you were looking for, try a new search!
Gynesonics Announces Publication of CHOICES: A Comparative Study of the Sonata Treatment VERSUS Myomectomy Sonata demonstrates significant advantages in reducing procedure time, length of stay and procedure related costs compared to myomectomy. Redwood City, CA, June 30, 2020 – Gynesonics®, [...]
The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the [...]
Early launch in Europe contributes to significant procedural growth Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance [...]
2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine [...]
What is Gynesonics about? How are you changing the standard of care in uterine fibroids? Gynesonics is focused on advancing women’s health by developing uterus-preserving, incision free, transcervical technology. Currently, we are focused on the treatment of symptomatic uterine fibroids, a [...]
Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal [...]
Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE Pivotal Trial 12-month [...]
Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity [...]
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that [...]
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the [...]